Trial Profile
A Double- Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jul 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Registrational; Therapeutic Use
- Acronyms VISTA-DME
- Sponsors Regeneron Pharmaceuticals
- 01 Jul 2023 Results of post-hoc analysis of two studies VISTA & VIVID assessing time to, cumulative incidence of, and functional benefit of achieving sustained ≥2-step Diabetic Retinopathy Severity Scale (DRSS) improvement in diabetic macular oedema, published in the Eye.
- 09 Jun 2015 Pooled results of sub-analysis of this and VIVID-DME trials (assessing visual outcome) presented at the 75th Annual Scientific Sessions of the American Diabetes
- 19 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.